Disclosed is a sustained-release lipid pre-concentrate, comprising: a) at least one liquid crystal former b) at least one neutral phospholipid c) at least one liquid crystal hardener and d) at least one anionic anchoring agent, wherein the sustained-release pre-concentrate exists as a lipid liquid phase in the absence of aqueous fluid and forms into a liquid crystal upon exposure to aqueous fluid. The sustained-release lipid pre-concentrate is configured to enhance the sustained release of cationic pharmacologically active substance through ionic interaction between the anionic anchoring agent and the cationic pharmacologically active substance.
